Peptidesearch
GLP-1 Enthusiast

COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' (HIMS.N), opens new tab platform, the Danish drugmaker said on Monday, ending a legal dispute that erupted last month.
The deal marks a turnaround from February, when Novo sued Hims over a $49 compounded alternative to its Wegovy weight-loss pill.
Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal dispute that erupted last month.
www.reuters.com
The deal marks a turnaround from February, when Novo sued Hims over a $49 compounded alternative to its Wegovy weight-loss pill.
Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal dispute that erupted last month.
www.reuters.com

